9 February 2021
AZD0466 clinical DEP® program global expansion
3 February 2021
Change in substantial holding
29 January 2021
Quarterly Cashflow and Activities Report
27 January 2021
Appendix 2A
18 January 2021
Change in substantial holding
18 January 2021
Change in substantial holding
24 December 2020
Change in substantial holding
22 December 2020
VIRALEZE COVID-19 nasal spray study to commence in January
22 December 2020
Change in substantial holding
10 December 2020
VIRALEZE™ COVID-19 nasal spray to be ready for market Q1CY21
24 November 2020
Change in Director's Interest Notice - J Fairley
24 November 2020
Appendix 3G
20 November 2020
2020 AGM Results
20 November 2020
Retirement of non-executive director Richard Hazleton
20 November 2020
AGM Chairman address and CEO presentation
19 November 2020
SPL7013 shows potent antiviral activity in RSV
13 November 2020
Appendix 3G
4 November 2020
Change in Director's Interest Notice - R Thomas
4 November 2020
Change in Director's Interest Notice - J Fairley
4 November 2020
Change in Director's Interest Notice - P Turvey

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com


This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.